Abstract Body

Background

CAB PrEP is highly effective but rare instances of HIV acquisition have occurred in trials and clinical care. HIV diagnosis among persons on CAB PrEP can be complicated by viremia suppression, delayed seroconversion, and false-positive HIV RNA results. We examined HIV detection, provider-selected ART or PrEP, and diagnostic outcomes in individuals with unconfirmed detectable plasma HIV RNA while on CAB PrEP in routine care. 

Methods

The SeroPrEP study is enrolling persons across the U.S. with evidence of potential HIV acquisition during use of oral or long-acting (LA) PrEP in routine care. PrEP/ART history and HIV RNA results were obtained from medical records. Blood samples were then collected for research assays: 5th generation antigen/antibody (Ag/Ab); HIV RNA single-copy assay (SCA) (limit of detection ≥1 c/ml); and cell-associated HIV DNA assay (CAD) in 20,000-400,000 purified CD4+ T cells.

Results

Among 9 participants (ppts) in this analysis with unconfirmed detectable HIV RNA on CAB PrEP, median age was 33 [range 29-56] years. After a median of 2 [range 1-11] CAB injections, all 9 had plasma HIV-1 RNA detected: qualitative reactive (N=2); detected, <30 c/mL (N=3); or detected >20 c/ml with median 64 [range 26 – 291] c/mL (N=4). A confirmatory quantitative RNA performed within median 7 [range 3-13] days was undetectable for 8/9 ppts (1 ppt had detected <20 c/mL). 5/9 ppts switched off CAB or had injection delays after initial detectable RNA. Research samples were collected at ≥1 visits, a median 25 (range 6-133) days after first detected HIV RNA result. Ag/Ab was non-reactive in 9/9 ppts. In 12/13 samples from 9 ppts, HIV RNA by SCA was ND; in 1 ppt SCA was 0.38 c/mL 6 days after the first detectable RNA. HIV-1 DNA was not detected by CAD in 9/9 ppts. Ppts were followed for clinical status for a median of 9 [range 4-19] months and 9/9 had undetectable quantitative HIV-1 RNA. Most recent regimens were CAB PrEP (N=5), F/TDF PrEP (N=2), F/TAF PrEP (N=1), darunavir/cobicistat/F/TAF ART (N=1). 

Conclusions

In individuals with a single detectable HIV RNA while on CAB PrEP in routine care, early follow-up with repeat clinical testing did not confirm an actual HIV diagnosis and most resumed use of a PrEP modality. Two participants had low level detectable RNA with repeat testing. Larger studies are needed to refine diagnostic testing strategies, including the utility of sensitive DNA and RNA assays, to resolve ambiguous test results and to inform clinical management for LA-PrEP.

Table or Figure